Cadrenal Therapeutics
CVKD
3 hedge funds and large institutions have $1.34K invested in Cadrenal Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.22K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$457 |
| 3 |
Wells Fargo
San Francisco,
California
|
+$30 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
1
Tower Research Capital (TRC)
New York
| $1K | +$1.22K | +40 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $324 | +$457 | +15 | New |
|
|
3
Wells Fargo
San Francisco,
California
| $14 | +$30 | +1 | New |
|
CVKD Hedge Fund Activity: Q1 2023 in Review
3 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cadrenal Therapeutics (CVKD) for Q1 2023, worth a combined $1.34K.
Buyers outnumbered sellers: 3 funds opened new CVKD positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $1.22K.
- 3 institutional investors held Cadrenal Therapeutics (CVKD) as of Q1 2023, up from 0 in Q4 2022.
- Funds reported $1.34K of Cadrenal Therapeutics stock for Q1 2023.
- 3 funds opened new Cadrenal Therapeutics positions in Q1 2023 and 0 closed out, a net change of +3 holders.
- The largest Cadrenal Therapeutics buyer in Q1 2023 was Tower Research Capital (TRC), an estimated $1.22K added.
Based on aggregated 13F filings for Q1 2023.